Peripubertal aromatase inhibition in male rats has adverse long-term effects on bone strength and growth and induces prostatic hyperplasia

Anurag Bajpai1,2, Peter J Simm1,2,3, Stephen J McPherson4, Vincenzo C Russo1,2,3, Walid J Azar1,2,3, John D Wark5, Gail P Risbridger4 and George A Werther1,2,3

1Department of Endocrinology and Diabetes, Royal Children's Hospital, Parkville, Melbourne, Victoria 3052, Australia
2Murdoch Children’s Research Institute, Centre for Hormone Research, Parkville, Melbourne, Victoria 3052, Australia
3Department of Paediatrics, University of Melbourne, Melbourne, Victoria 3052, Australia
4Prostate and Breast Cancer Research Group, Department of Anatomy and Developmental Biology, Monash University, Clayton, Victoria 3800, Australia
5Department of Medicine and Bone and Mineral Service, The Royal Melbourne Hospital, University of Melbourne, Melbourne, Victoria 3052, Australia

(Correspondence should be addressed to P J Simm at Department of Endocrinology and Diabetes, Murdoch Childrens Research Institute, Centre of Hormone Research, Royal Children's Hospital; Email: peter.simm@mcri.edu.au)

Abstract

Aromatase inhibitors have been increasingly used in boys with growth retardation to prolong the duration of growth and increase final height. Multiple important roles of oestrogen in males point to potential adverse effects of this strategy. Although the deleterious effects of aromatase deficiency in early childhood and adulthood are well documented, there is limited information about the potential long-term adverse effects of peripubertal aromatase inhibition. To address this issue, we evaluated short-term and long-term effects of peripubertal aromatase inhibition in an animal model. Peripubertal male Wistar rats were treated with aromatase inhibitor letrozole or placebo and followed until adulthood. Letrozole treatment caused sustained reduction in bone strength and alteration in skeletal geometry, lowering of IGF1 levels, inhibition of growth resulting in significantly lower weight and length of treated animals and development of focal prostatic hyperplasia. Our observation of adverse long-term effects after peripubertal male rats were exposed to aromatase inhibitors highlights the need for further characterisation of long-term adverse effects of aromatase inhibitors in peripubertal boys before further widespread use is accepted. Furthermore, this suggests the need to develop more selective oestrogen inhibition strategies in order to inhibit oestrogen action on the growth plate, while beneficial effects in other tissues are preserved.

Introduction

The crucial role of oestrogen in mediating epiphyseal fusion in males was established by classical reports of men with defective oestrogen synthesis (aromatase deficiency; Morishima et al. 1995) and action (oestrogen receptor α deletion; Smith et al. 1994). These men in their twenties had tall stature and open epiphyses despite normal pubertal development and testosterone levels, indicating that oestrogen, and not testosterone, was responsible for epiphyseal fusion in men. This realisation prompted the development of a novel treatment for boys with short stature using aromatase inhibitors, which block oestrogen production in order to prolong the duration of growth and to increase final height. Beneficial effects of aromatase inhibitors on growth have been reported in boys with constitutional delay of puberty and growth, idiopathic short stature and GH deficiency (Wickman et al. 2001, Mauras et al. 2004, 2008, Hero et al. 2003, 2006a). The ease of administration, low cost and lack of overt toxicity of aromatase inhibitors make them a potential attractive strategy for treatment of boys with idiopathic short stature. This has led to a significant increase in the use of aromatase inhibitors in short boys, especially in North America and Europe (Shulman et al. 2008).

The use of aromatase inhibitors in young boys, however, remains ‘off label’, as these agents were primarily developed for the treatment of hormone-responsive breast cancer and preclinical studies were not performed in peripubertal males. Short-term follow-up (2–3 years) of boys treated with aromatase inhibitors has not shown significant adverse effects on areal bone density (Wickman et al. 2003), body composition (Hero et al. 2006a) or spermatogenesis (Maurus et al. 2005). However, these studies are limited by small sample size and short duration of follow-up. Importantly, many adverse effects of aromatase inhibition may not be manifested until adulthood. A fundamental assumption for the use of aromatase inhibitors in boys is that oestrogen deficiency has no deleterious consequences. However, this proposition is questioned by the important physiological role of oestrogen in males as illustrated by the development of osteoporosis.
(Bilezikian et al. 1998, Oz et al. 2000), adiposity phenotype (Morishima et al. 1995, Jones et al. 2000, Takeda et al. 2003) and impaired spermatogenesis (Carani et al. 1997, Robertson et al. 1999, Murata et al. 2002) in aromatase-deficient men and mice. These models, however, indicate the effects of long-standing oestrogen deficiency and are therefore not representative of selective peripubertal aromatase inhibition. Deleterious skeletal (Vanderschueren et al. 1997) and testicular (Turner et al. 2000) effects in adult Wistar rats treated with aromatase inhibitors suggest the potential of adverse effects of transient aromatase deficiency. However, the effects of transient aromatase inhibition in peripubertal males remain largely unexplored. We therefore developed an animal model to study these effects. In our study, peripubertal male Wistar rats were treated with letrozole, a highly selective, non-steroidal aromatase inhibitor. They were then followed up until early adulthood. The use of this model allowed us to study the long-term consequences of aromatase inhibition in peripubertal males.

Materials and Methods

The study was conducted at the large animal facility of the Royal Children's Hospital, Melbourne, Australia, in accordance with the Australian Code of Practice for the care and use of animals for scientific purposes, 2004. Ethical approval was obtained from the Animal Ethics Committee of the Royal Children’s Hospital (AEC number 554).

Animals

Fifty 27-day-old male Wistar rats were obtained from Central Animal Services, Monash University, Clayton, Australia. After 3 days of acclimatisation, they were randomised to treatment (n = 25) and control (n = 25) groups. The animals were housed individually in similar environmental conditions (reverse day–night cycle with 12 h day and night, temperature 24 °C). They were fed oestrogen-free diet (AIN93M, Specialty Feeds, Perth, Western Australia, Australia) to avoid the confounding effect of environmental oestrogen exposure. No dietary- or water restrictions were imposed. The animals were inspected daily for well-being and weighed bi-weekly.

Intervention

The treatment group received letrozole orally (Femara, Novartis group, 1 mg/kg per day dissolved in 10% gelatin; Nolan & Levy 2006). The gelatin preparation was consumed avidly by the rats. They were treated from the peripubertal age of 30 days for 60 days until the age of 90 days. This is roughly equivalent of ages 10–18 years in human terms. The control animals received gelatin vehicle alone. The animals were followed for an additional 90 days after completion of treatment until adulthood at the age of 180 days, which equates to around 30 human years of age (Fig. 1). Blood was obtained from the tail vein at the start of study (day 0), at the end of treatment (day 60) and at the end of study (day 150). Serum was separated and stored at –70 °C until analysis. The animals were culled by injecting pentobarbital (0.5 ml of 340 mg/ml; Virbac Animal Health, NSW, Australia).

Blood assays

Blood glucose was measured using a Medisense Optimum glucometer (Abbott Laboratories); insulin-like growth factor 1 (IGF1) was measured using a rat/mouse IGF1 ELISA (Immunodiagnostic Systems Ltd (IDS), Fountain Hill, AZ, USA) with intra- and inter-assay coefficients of variation (CV) of 4.3–8.8% and 6.3–8.8% respectively. A rat/mouse GH kit (Linco Diagnostics, St Charles, MO, USA) was used for measurement of GH (intra-assay CV 1.7–4.3%; inter-assay CV 3.2–4.9%) on a single sample. Bone turnover was assessed with the bone formation marker serum osteocalcin (rat osteocalcin EIA kit, Biomedical Technology Inc., Stoughton, MA, USA; intra-assay variation 4%; inter-assay variation 7%) and the bone resorption marker C-terminal telopeptide of type I collagen (RATLAPS from IDS; intra-assay variation <10%, inter-assay variation <15%). LH and FSH were measured by RIA with the following iodinated preparations (iodinated using Iodogen reagent (Sigma) and anti-sera: recombinant (r) FSH 1–8 and anti-rFSH-S-11, and rLH-1–9 and anti-rLH-S-10 (NIDDK, Bethesda, MD, USA)). The secondary antibody used in both RIAs was goat anti-rabbit IgG (GAR no. 12; Monash Institute of Reproduction and Development, Monash University, Melbourne, Australia), and the assay buffer was 0.01 M PBS containing 0.5% BSA (Sigma). All samples were measured in a single assay as described previously (O’Donnell et al. 1994). Serum levels of testosterone were determined using the DSL-4000-coated tube RIA as per the manufacturer’s instructions (Diagnostic System Laboratories Inc., Webster, TX, USA). Insulin (intra-assay CV 1.4–3.6%; inter-assay CV 6.71–9.23%) levels were measured using kits from Linco Diagnostics.

Figure 1 Results from bone turnover markers. (a) No significant difference in bone formation, as assessed by measuring serum osteocalcin levels, was observed between treated and non-treated animals. (b) Bone resorption, as assessed by RATLAPS assay, was significantly reduced in letrozole-treated animals as compared to controls.
Dual energy X ray absorptiometry

Dual energy X ray absorptiometry (DXA) was performed at the end of treatment (day 60) and at the end of study (day 150) using a QDR 4500A densitometer (Hologic Inc., Bedford, MA, USA) with dedicated small animal software (V9 L1 Rev A for acquisition and rat whole body V8.26a for analysis). Total mass, lean mass, fat mass and percentage of body fat were determined by whole body DXA. Tibial and crown–rump lengths were measured using the DXA image at both time points.

Peripheral quantitative computed tomography

Peripheral quantitative computed tomography (PQCT) of the tibia was performed at the end of treatment (day 60) and at the end of study (day 150) using an XCT Research SA densitometer (Stratec Medizintechnik GmbH, Pforzheim, Germany) by a single-blinded observer. Two CT slices were obtained at distances of 4 and 30% tibial length from the end of the left tibia to assess trabecular and cortical bone respectively. Contour mode 1 and peel mode 20 were used for analysis. A voxel size of 0·1 mm was selected. Cross-sectional bone area and volumetric bone density were calculated at both sites. Cortical thickness, periosteal circumference, endosteal circumference and stress–strain index were measured at the 30% site.

Prostate

The weight of individual lobes of the prostate was measured at the time of culling. Prostate was fixed in modified Bouin’s solution, embedded in paraffin and cut into 5 μm sections as described earlier. Tissue sections were stained with haematoxylin and eosin to study morphological changes or subjected to immunohistological examination using antibodies to proliferating cell nuclear antigen (PCNA; PC10; Dako Corp., Carpinteria, CA, USA) or Apoptag. Analyses of PCNA and apoptotic marker immunolocalisation were conducted using CAST software (version 2.1.4; Olympus Corp., Albertslund, Denmark) as described earlier (McPherson et al. 2001).

Testes

The weight of both testes was measured at the end of study. The testis was fixed in Bouin’s solution and transferred into 70% ethanol. Testicular histology evaluation included assessment for disruption of spermatogenesis, and immunohistochemical analysis of cellular proliferation and apoptosis.

Statistical analysis

The study was powered to detect a difference of 1 SDS in stress–strain index with a power of 80% and a level of significance of 0·05. Seventeen animals were required in each group. We enrolled 25 animals in each group to allow for attrition. Data were expressed as mean ± S.D. SPSS version 10 (IL, USA) was used for statistical analysis. Quantitative parameters in the two groups were analysed using a two-tailed unpaired Student’s t-test. A P value < 0·05 was considered significant.

Results

Of the 25 animals in each group, 5 (3 in the treatment group and 2 controls) died due to anaesthetic complications. Data for 22 animals in the treatment group and 23 animals in the control group are presented.

Skeleton

PQCT showed lower cross-sectional trabecular and cortical bone area in the treated animals (Table 1). This was associated with reduced periosteal and endosteal circumference and cortical thickness at the 30% tibial (cortical) site.

### Table 1 Peripheral quantitative computed tomography skeletal parameters observed in the study

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Treatment</th>
<th>Control</th>
<th>P</th>
<th>Treatment</th>
<th>Control</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trabecular cross sectional area (mm²)</td>
<td>15·5 ± 1·2</td>
<td>18·7 ± 0·9</td>
<td>&lt;0·0001</td>
<td>18·0 ± 1·1</td>
<td>20·5 ± 1·6</td>
<td>&lt;0·0001</td>
</tr>
<tr>
<td>Trabecular density (mg/mm³)</td>
<td>403·3 ± 28·1</td>
<td>401·7 ± 37·6</td>
<td>0·87</td>
<td>448·2 ± 39·1</td>
<td>435·7 ± 51·9</td>
<td>0·37</td>
</tr>
<tr>
<td>Cortical cross sectional area (mm²)</td>
<td>4·6 ± 0·3</td>
<td>5·8 ± 0·4</td>
<td>&lt;0·0001</td>
<td>6·1 ± 0·4</td>
<td>7·4 ± 0·6</td>
<td>&lt;0·0001</td>
</tr>
<tr>
<td>Cortical density (mg/mm³)</td>
<td>1207·0 ± 16·7</td>
<td>1210·7 ± 28·4</td>
<td>0·62</td>
<td>1275·9 ± 13·1</td>
<td>1279·3 ± 12·7</td>
<td>0·38</td>
</tr>
<tr>
<td>Cortical thickness (mm)</td>
<td>0·50 ± 0·03</td>
<td>0·60 ± 0·03</td>
<td>&lt;0·0001</td>
<td>0·70 ± 0·02</td>
<td>0·73 ± 0·03</td>
<td>0·002</td>
</tr>
<tr>
<td>Cortical thickness/TL (mm/cm)</td>
<td>0·138 ± 0·011</td>
<td>0·148 ± 0·011</td>
<td>0·005</td>
<td>0·166 ± 0·012</td>
<td>0·157 ± 0·009</td>
<td>0·01</td>
</tr>
<tr>
<td>Periosteal circumference (mm)</td>
<td>10·6 ± 0·4</td>
<td>11·8 ± 0·7</td>
<td>&lt;0·0001</td>
<td>11·0 ± 0·5</td>
<td>12·4 ± 0·7</td>
<td>&lt;0·0001</td>
</tr>
<tr>
<td>Periosteal circumference/TL (mm/cm)</td>
<td>2·84 ± 0·28</td>
<td>2·99 ± 0·21</td>
<td>0·05</td>
<td>2·62 ± 0·13</td>
<td>2·68 ± 0·18</td>
<td>0·23</td>
</tr>
<tr>
<td>Endosteal circumference (mm)</td>
<td>7·4 ± 0·5</td>
<td>8·1 ± 0·8</td>
<td>0·001</td>
<td>6·7 ± 0·6</td>
<td>7·8 ± 0·6</td>
<td>&lt;0·0001</td>
</tr>
<tr>
<td>Endosteal circumference/TL (mm/cm)</td>
<td>1·97 ± 0·26</td>
<td>2·06 ± 0·20</td>
<td>0·23</td>
<td>1·58 ± 0·09</td>
<td>1·69 ± 0·15</td>
<td>0·006</td>
</tr>
<tr>
<td>Stress–strain index (mm³)</td>
<td>4·0 ± 0·5</td>
<td>5·6 ± 0·5</td>
<td>&lt;0·0001</td>
<td>5·1 ± 0·5</td>
<td>7·0 ± 1·1</td>
<td>&lt;0·0001</td>
</tr>
</tbody>
</table>

TL, tibial length.
No difference was seen between the cortical and trabecular volumetric bone mineral density in the two groups. Treated animals had reduced linear skeletal growth as reflected by lower tibial length at the end of treatment (37.2±2.6 vs 40.8±1.7 mm, *P*<0.0001) and at the end of study (40.8±1.9 vs 46.4±2.5 mm, *P*<0.0001). When the skeletal geometry results were corrected for this reduced tibial length (Table 1), there was a significant reduction in cortical thickness/tibial length ratio and peristomal circumference/tibial length ratio at day 60 in the treated animals, whereas endostomal circumference to tibial length ratio showed a trend towards reduction. These skeletal changes resulted in a reduction in bone strength as reflected by lower stress–strain index in the treated animals.

At day 150, previously treated animals had a significantly decreased endostomal circumference/tibial length ratio, leading to an increased cortical thickness/tibial length ratio in the treatment group. The smaller bones, however, still showed a reduced stress–strain index at day 150.

Osteocalcin levels in treated animals were not significantly different from those measured in the control animals (letrozole (n=17) 9.35±0.2841 ng/ml versus control (n=19) 8.22±0.5438 ng/ml, *P*=0.0835; Fig. 1a), but letrozole-treated animals had lower RATLAPS levels (47.3±8.6 vs 58.1±7.4 ng/ml, *P*=0.0003; Fig. 1b) than controls at the end of treatment.

Growth

The two groups had similar weight at the start of study. Treated animals had lower relative weight gain during treatment compared to controls (179.1±32.3 vs 354.3±57.8%, *P*<0.0001) resulting in significantly lower weight than controls from day 10 onwards. The weight of treated animals was 37.5% lower than controls. Both groups had similar relative weight gain (37.7±7.2 vs 34.7±7.9%, *P*=0.31) in the follow-up period; the weight of the treated animals, however, remained 36.2% lower than controls at the end of study. IGF1 levels were similar in the two groups at the start of study (1475±95.87 vs 1316±63.71 ng/ml, *P*=0.21); levels were lower in the treated animals at the end of treatment (1051.6±268.8 vs 1706.2±244.2 ng/ml, *P*<0.0001) and at the end of study (1682±40.53 vs 2282±53.51 ng/ml, *P*<0.0001).

A group had similar relative weight gain (37.7±7.2 vs 34.7±7.9%, *P*=0.31) in the follow-up period; the weight of the treated animals, however, remained 36.2% lower than controls at the end of study (*P*<0.0001). Linear growth was also compromised in the treatment group with lower crown-rump length and tibial length at the end of treatment and at the end of study (*P*<0.0001 for both). IGF1 levels were similar in the two groups at the start of study (1475±95.87 vs 1316±63.71 ng/ml; *P*=0.21); levels were lower in the treated animals during treatment (1051.6±268.8 vs 1706.2±244.2 ng/ml, *P*<0.0001) and at the end of study (1682±40.53 vs 2282±53.51 ng/ml, *P*<0.0001; Fig. 2b). GH levels were unaffected by letrozole treatment (21.7±22.9 vs 31.8±22.4 ng/ml, *P* not significant).

Prostate

Letrozole-treated animals had larger anterior and dorsal lobes of prostate at the end of study when corrected for body weight (Table 3). No difference was noted in the weight of ventral and lateral prostate lobes corrected for body weight. Focal prostatic hyperplasia was observed in 15/19 treated animals (78.9%) with 4.8±2.6 foci per tissue (Fig. 3a). None of the controls showed focal prostatic hyperplasia. A trend of

### Table 2 Growth parameters observed in the study

| Category                  | Treatment (n=22) | Control (n=23) | *P*
|---------------------------|-----------------|----------------|--------
| Weight (g)                |                 |                |        |
| Day 0                     | 101.4±13.5      | 100.2±9.9      | 0.72   |
| Day 60                    | 284.2±27.4      | 455.2±43.8     | <0.0001|
| Day 150                   | 391.3±40.0      | 613.3±80.0     | <0.0001|
| Weight gain % of baseline |                 |                |        |
| Day 1–60                  | 179.1±32.3      | 354.3±57.8     | <0.0001|
| Day 61–150                | 37.7±7.2        | 34.7±7.9       | 0.31   |
| Crown–rump length (cm)    |                 |                |        |
| Day 60                    | 17.5±0.8        | 19.4±0.7       | <0.0001|
| Day 150                   | 18.7±0.5        | 21.1±0.6       | <0.0001|
| Tibial length             |                 |                |        |
| Day 60                    | 37.2±2.6 (mm)   | 42.0±1.7 (mm)  | <0.0001|
| Day 150                   | 40.8±1.9 (mm)   | 46.4±2.5 (mm)  | <0.0001|

---

Image [328x482 to 519x544]

---

*Figure 2* Effects of aromatase inhibitors on growth. (a) Treated animals had lower relative weight gain during treatment compared to controls (179.1±32.3 vs 354.3±57.8%, *P*<0.0001) resulting in significantly lower weight than controls from day 10 onwards. The weight of treated animals was 37.5% lower than controls. Both groups had similar relative weight gain (37.7±7.2 vs 34.7±7.9%, *P*<0.0001) in the follow-up period; the weight of the treated animals, however, remained 36.2% lower than controls at the end of study. (b) IGF1 levels were similar in the two groups at the start of study (1475±95.87 vs 1316±63.71 ng/ml, *P*=0.21); levels were lower in the treated animals at the end of treatment (1051.6±268.8 vs 1706.2±244.2 ng/ml, *P*<0.0001) and at the end of study (1682±40.53 vs 2282±53.51 ng/ml, *P*<0.0001).
increased percentage of PCNA-positive epithelial cells was observed in the treated group compared to controls (4.27 ± 1.28 vs 2.17 ± 0.43, *P* = 0.054; Fig. 3b).

**Reproductive measures**

Testicular size was increased in the treated animals at the end of study, as reflected by higher testicular weight corrected for body weight (Table 3). Letrozole treatment was associated with a reduction in LH levels. The two groups had similar levels at the start of treatment (0.28 ± 0.24 vs 0.36 ± 0.26 ng/ml, *P* = 0.318). LH levels were lower in the treatment group at day 60 (0.39 ± 0.33 vs 0.69 ± 0.27 ng/ml, *P* < 0.0001) and were similar by the end of study (0.98 ± 0.32 vs 1.1 ± 0.57 ng/ml, *P* = 0.28).

**Table 3 Organ weights of prostate and testis at the end of study** (expressed as g/100 g body weight)

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Treatment</th>
<th>Control</th>
<th><em>P</em></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(n = 22)</td>
<td>(n = 23)</td>
<td></td>
</tr>
<tr>
<td>Ventral prostate</td>
<td>0.099 ± 0.020</td>
<td>0.105 ± 0.021</td>
<td>0.28</td>
</tr>
<tr>
<td>(g/100 g)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anterior prostate</td>
<td>0.043 ± 0.009</td>
<td>0.035 ± 0.007</td>
<td>0.003</td>
</tr>
<tr>
<td>(g/100 g)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lateral prostate</td>
<td>0.036 ± 0.012</td>
<td>0.034 ± 0.009</td>
<td>0.57</td>
</tr>
<tr>
<td>(g/100 g)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dorsal prostate</td>
<td>0.060 ± 0.016</td>
<td>0.051 ± 0.012</td>
<td>0.08</td>
</tr>
<tr>
<td>(g/100 g)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Testis (g/100 g)</td>
<td>0.877 ± 0.117</td>
<td>0.634 ± 0.113</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

Body composition and metabolic parameters

Letrozole treatment did not affect the proportion of fat mass at the end of treatment (20.2 ± 4.8 vs 19.4 ± 4.7%, *P* = 0.58). Treated animals, however, had a lower proportion of body fat at the end of study (23.5 ± 5.8 vs 30.1 ± 7.0%, *P* < 0.0001). The insulin to glucose ratio was similar in the two groups during treatment (0.37 ± 0.15 vs 0.43 ± 0.26, *P* = 0.38).

**Figure 3** Effects of letrozole treatment on prostate. (a) Focal prostatic hyperplasia was observed in 15/19 treated animals (78-9%) with 4.8 ± 2.6 foci per tissue. None of the controls showed focal prostatic hyperplasia. (b) Letrozole-treated animals showed a trend of increased percentage of PCNA-positive epithelial cells compared to controls (4.27 ± 1.28 vs 2.17 ± 0.43, *P* = 0.054). Solid bars represent letrozole-treated animals and open bars represent controls (mean ± S.D.).

**Discussion**

Our study has demonstrated significant long-term adverse effects of aromatase inhibition in peripubertal male rats. Peripubertal aromatase inhibition led to reduction in bone strength, impaired growth and prostatic hyperplasia. Importantly, these effects were long standing and persisted in adulthood.

The demonstration of persistent compromise in bone strength in the letrozole-treated animals was a critical finding in our study. This reiterates the observations of reduced bone strength in aromatase-deficient men (Bilezikian et al. 1998), aromatase knockout mice (Oz et al. 2000) and older male Wistar rats treated with aromatase inhibitor vorozole (Vanderschueren et al. 1997). In the first two models, however, aromatase inhibition was lifelong, whereas in the last model, aromatase inhibition only occurred in adulthood. In contrast, in our model, aromatase inhibition was limited to the peri-pubertal period, similar to its current usage in short boys. Abnormalities in skeletal geometry (reduced periosteal and endosteal circumference, bone length and cortical thickness), with resultant smaller, thinner bones, even when corrected for tibial length, were seen in letrozole-treated animals. However, bone mineral density was preserved. This suggests a direct inhibitory effect of the drug on periosteal apposition over and above the changes observed in linear growth. Treated animals showed catchup in bone size and periosteal apposition after discontinuation of treatment resulting in similar bone size corrected for tibial length in the two groups at last follow-up. The reduced stress–strain index observed at the end of study thus pertains to the small overall size of the bone. However, this smaller bone is still at increased risk of fracture compared to the larger bones observed in the control animals.

The change in bone geometry, but not density, indicates a differential role of oestrogen in the male skeleton with predominant effect on skeletal growth and cortical modelling and relatively minor effect on bone mass accrual. This is in concordance with the observations on growing wild-type and androgen receptor knockout male mice (Venken et al. 2006). The lack of variation in osteocalcin results and reduced bone
resorption reflected by the RATLAPS assay between treated and untreated animals at this dose are consistent with the only published data in rats (Kumru et al. 2007). Given that osteocalcin reflects only one aspect of osteoblast function, it is possible that effects are being mediated on bone formation, which are not seen in the osteocalcin results.

Our findings highlight the limitations of the currently available evidence regarding bone safety in aromatase inhibitor-treated boys. These studies have assumed a lack of adverse skeletal effects by the demonstration of similar DXA-measured areal bone mineral density (BMD) and bone markers compared to controls, and have not used PQCT scans. Importantly, DXA does not provide robust information about skeletal geometry, the main site of oestrogen action. In three out of four of these studies, testosterone or GH, agents with direct anabolic effects on bone, was used in addition to aromatase inhibitors. Although aromatase inhibitors may be combined with GH and testosterone in boys with GH deficiency and constitutional delay of puberty and growth respectively, they are frequently used as a stand-alone treatment in idiopathic short stature, the most common indication in clinical practice. The observations of studies with combination treatment cannot be extrapolated to boys with idiopathic short stature. Another important factor in these studies is the relatively short follow-up duration (1–3 years). With fragility fracture the most important long-term indicator of bone health, the finding of vertebral compression in aromatase inhibitor-treated boys within 10 years of the initial treatment is particularly important (Dunkel 2009, Hero et al. 2009) and that this occurred despite normal DXA-measured areal BMD suggests that areal BMD is not an adequate predictor of bone strength in this setting.

A second significant observation of our study was the growth suppression induced by letrozole, with treated animals weighing 37.5% less than controls. This is similar to the observation of Vandescheuren et al. (1997) showing 16% lower weight in vorozole-treated growing Wistar rats, and Turner et al. (2000) showing 24% lower weight in anastrozole-treated adult male rats. Intriguingly, Eshet et al. (2004) observed increased weight gain in male mice treated with letrozole for 10 days. This is consistent with reports in female letrozole-treated rats, which showed weight gain and changes consistent with polycystic ovarian syndrome (Manneras et al. 2007). Our study examining male rats only is not able to shed further light on the discrepancy between reports in different genders. Importantly, impairment in weight gain in males was evident only after 2 weeks of treatment in our and other studies, as distinct from females. Longer duration of treatment is thus expected to result in growth inhibition as observed in our study. This could represent effects of oestrogen deficiency or toxic effects of the drug. However, no toxic effects were observed during the study, with the only deaths being due to anaesthetic complications. Although food intake was not formally quantified, feeding behaviour and activity were similar in treated and control animals, arguing against a toxic effect of the drug. The growth-suppressing effect of aromatase inhibition may be due to inhibition of IGF1 production due to effects of oestrogen deficiency on GH receptor expression or signalling, or loss of GH–independent hepatic production of IGF1 (Venken et al. 2005). Although this impaired weight gain may partially explain the observed skeletal phenotype, it would seem that even in the female model where there is weight gain, the amount of bone formation as measured by bone mineral content per weight is reduced, suggesting a direct effect of letrozole in impaired bone mass accrual in both genders (Manneras et al. 2007).

The third important finding of our study was the demonstration of focal prostatic hyperplasia along with increased size of the anterior and dorsal prostate lobes (when corrected for body weight) in letrozole-treated animals. As for the other novel findings, these changes were apparent well beyond the treatment period to at least the equivalent of human age of 30 years. The balance of androgens and oestrogen is critical in both prostate physiology and pathologies (Harkonen & Makela 2004, Prins et al. 2006, McPherson et al. 2008). Perturbation leading to hormonal imbalance in early neonatal life or on aging causes prostatic pathologies (Prins et al. 2007). The demonstration of prostatic hyperplasia due to short-term aromatase inhibition in peripubertal animals is entirely consistent with the observation that long-term oestrogen deficiency causes prostatic hyperplasia and hypertrophy in adult aromatase knockout (ArKO) mice (McPherson et al. 2001). These observations indicate the need for long-term follow-up for evaluation of prostatic health in young boys treated with aromatase inhibitors.

Adverse testicular effects are an important area of concern in the use of aromatase inhibitors in boys in view of impaired spermatogenesis in adult male ArKO mice (Robertson et al. 1999) and one man with aromatase deficiency (Carani et al. 1997). Although the testicular size of treated animals was increased when corrected for body weight, no obvious abnormality in testicular histology was observed in our study. Treatment with anastrazole for up to 1 year in adult male Wistar rats, however, resulted in the development of Sertoli cells–only tests in 10% of animals, with varying degrees of germ cell loss in 1–2% of seminiferous tubules (Turner et al. 2000). These findings suggest that severe adverse testicular effects of aromatase deficiency may manifest only after prolonged oestrogen deficiency, as seen in male ArKO mice, which are initially fertile, and impaired spermatogenesis occurs as a late event (Robertson et al. 1999).

The tissue effects of aromatase inhibitors in males are largely related to local oestrogen deficiency, as locally produced oestrogen plays a much more important role compared with circulating oestradiol (E2) in males. Tissue E2 levels are therefore more relevant than circulating E2 levels. Studies on aromatase inhibition have failed to detect a difference in circulating E2 levels despite evident effect on the hypothalamic–pituitary axis (Turner et al. 2000). E2 levels were undetectable by the methods used in the study. Testosterone levels were not elevated in the treated animals at the end of treatment. This may be related to the fact that testosterone
levels were measured after 60 days of treatment. Importantly, Turner et al. in a study of effects of anastrozole in older male Wistar rats observed that although testosterone levels were higher in treated animals initially, no significant difference was observed between groups for either testosterone or FSH levels after prolonged treatment. Similarly, we were unable to demonstrate pituitary effects from assessment of FSH levels as the samples were taken only after cessation of treatment.

In contrast to observations in aromatase knockout mice (Jones et al. 2000) and aromatase-deficient men (Morishima et al. 1995) who develop an adiposity phenotype and insulin resistance, no effect of aromatase inhibition on body composition and insulin levels was observed at the end of treatment.

In summary, our study has demonstrated adverse effects of aromatase inhibition on skeleton, growth and prostate in peripubertal male rats. Although caution needs to be exercised in extrapolating these findings into the clinic due to the longer duration of aromatase inhibitor treatment in our animal model and possible species differences in drug response, the findings nevertheless point to serious potential long-term adverse effects of such therapy in peripubertal short boys. Further characterisation of long-term adverse effects of aromatase inhibitors in animal models of peripubertal males is thus highly desirable before further widespread use in young boys. Our findings also point to the need for developing selective oestrogen inhibition strategies such that oestrogen action on growth plate is inhibited, while beneficial effects in other tissues are preserved.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

The study was supported by an unrestricted investigator initiated research grant from Pfizer Australia to GAW (AUS-NDE-07-002) and funding from the National Health and Medical Research Council (545931).

Author contribution statement

The study was conducted in the laboratories of GAW, JDW and GPR. AB conceived the study. AB, GAW, VCR, JDW and GPR were involved in the planning and implementation of the study. PJS, SJM and WJA contributed to the conduct of the study. AB collected data, performed the data analysis and drafted the manuscript. All the authors reviewed and contributed to the final version of the manuscript.

Acknowledgements

The authors acknowledge the significant role of Mr Magdy Sourial, Officer, Animal Research Laboratory, Royal Children’s Hospital, Melbourne, Victoria, Australia and Mrs Sue Kantor, Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia, in the conduct of the study.

References


Dunkel L 2009 Update on the role of aromatase inhibitors in growth disorders. *Hormone Research* 71 (Supplement 1) 57–63. (doi:10.1159/000178040)


McPherson SJ, Wang H, Jones ME, Pedersen J, Ismaa TP, Wreford N, Simpson ER & Risbridger GP 2001 Elevated androgens and prolactin in...


Received in final form 1 July 2010
Accepted 23 July 2010
Made available online as an Accepted Preprint 30 July 2010